
IRIDEX Corporation
IRIXNASDAQHealthcareMedical - Devices
一般交易時段
US$0.7571
+US$0.001 · +0.13%
IRIX公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
67
Undervalued
動能
48
Neutral
情緒
53
Mixed
風險韌性
46
Elevated Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- US
- 執行長
- Patrick Mercer
- 上市以來
- 1996年2月16日
- 僱員
- 93
市場位置
日內區間
目前US$0.7571,
52週區間
目前US$0.7571,
- 開盤價
- US$0.75
- 前收盤價
- US$0.7561
- 成交量
- 7.06萬
- 1.06× 平均值
- 平均成交量
- 6.64萬
- 日均成交量
- 市值
- 1310.34萬 USD
- 貝塔
- 0.64
- 市場參考 1
- 50天平均值
- US$0.9884
- 低於平均水平-23.40%
- 200天平均值
- US$1.1201
- 低於平均水平-32.41%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 1861.28萬 USD
- 本益比(TTM)
- -3.72×
- 股價淨值比(TTM)
- 3.62×
- 股價營收比(TTM)
- 0.25×
- EV/EBITDA
- -6.57×
- 盈餘收益率
- -22.06%
- 自由現金流收益率
- -11.23%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 36.23%
- 營業利益率
- -5.39%
- 淨利潤率
- -6.88%
- 股東權益報酬率
- -90.15%
- 資產報酬率
- -15.22%
- 投入資本報酬率
- -15.45%
財務健康
- 負債權益比
- 1.1×
- 流動比率
- 1.91×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5267.5萬 USD | 4866.9萬 USD | 5186.9萬 USD | 5697.2萬 USD | 5390.3萬 USD |
| 銷貨成本 | 3336.9萬 USD | 2916.7萬 USD | 3006.2萬 USD | 3160.4萬 USD | 3107.2萬 USD |
| 毛利 | 1930.6萬 USD | 1950.2萬 USD | 2180.7萬 USD | 2536.8萬 USD | 2283.1萬 USD |
| 研究與開發 | 366.8萬 USD | 544.9萬 USD | 682.9萬 USD | 717.5萬 USD | 686.8萬 USD |
| 銷售、一般及管理費用 | 1813萬 USD | 2235.5萬 USD | 2498.5萬 USD | 2573.5萬 USD | 2349.6萬 USD |
| 營業費用 | 2187.7萬 USD | 2780.4萬 USD | 3181.4萬 USD | 3291萬 USD | 3036.4萬 USD |
| 折舊和攤銷 | 154.7萬 USD | 142.4萬 USD | 203.2萬 USD | 138.4萬 USD | 80.3萬 USD |
| 營業利益 | −257.1萬 USD | −830.2萬 USD | −1000.7萬 USD | −754.2萬 USD | −753.3萬 USD |
| 淨利 | −443.7萬 USD | −891萬 USD | −957萬 USD | −754.7萬 USD | −522.5萬 USD |
公司資料更新於 2026年8月24日。
分析師評級
第三方分析師預期可能變動,並非 GoAI 建議。
評級分佈
4項評級評級樣本有限,僅4項
IRIX同業公司
持有IRIX的ETF
報告持有此股票曝險的交易所交易基金。
繼續GoAI的研究
在 GoAI 中研究IRIXresearch.disclaimer







